Kairos Pharma, Ltd.
KAPA
$0.34
-$0.02-5.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -64.85% | -109.26% | -84.68% | -134.85% | -78.08% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 53.33% | 234.78% |
| Total Other Non-Cash Items | 716.84% | 733.96% | 29.92% | 93.76% | -59.91% |
| Change in Net Operating Assets | 38.47% | 59.38% | -1.45% | -402.94% | -289.85% |
| Cash from Operations | 20.02% | 13.00% | -99.42% | -21,468.00% | -3,864.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 2,436.62% | 2,436.62% | 2,436.62% | 157.84% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -92.02% | 884.10% | 761.90% | 901.78% | 723.76% |
| Cash from Financing | -53.85% | 29.72% | 25.25% | 3,640.25% | 1,973.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.35% | 173.03% | -24.37% | 1,527.96% | 1,228.08% |